A new ALK inhibitor overcomes resistance to first‐ and second‐generation inhibitors in NSCLC
Authors:
Open Access
- 30 November 2021
- journal article
- research article
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 14 (1) , e14296
Abstract
More than 60% of nonsmall cell lung cancer (NSCLC) patients show a positive response to the first ALK inhibitor, crizotinib, which has been used as the standard treatment for newly diagnosed patients with ALK rearrangement. However, most patients inevitably develop crizotinib resistance due to acquired secondary mutations in the ALK kinase domain, such as the gatekeeper mutation L1196M and the most refractory mutation, G1202R. Here, we develop XMU‐MP‐5 as a new‐generation ALK inhibitor to overcome crizotinib resistance mutations, including L1196M and G1202R. XMU‐MP‐5 blocks ALK signaling pathways and inhibits the proliferation of cells harboring either wild‐type or mutant EML4‐ALK in vitro and suppresses tumor growth in xenograft mouse models in vivo . Structural analysis provides insights into the mode of action of XMU‐MP‐5. In addition, XMU‐MP‐5 induces significant regression of lung tumors in two genetically engineered mouse (GEM) models, further demonstrating its pharmacological efficacy and potential for clinical application. These preclinical data support XMU‐MP‐5 as a novel selective ALK inhibitor with high potency and selectivity. XMU‐MP‐5 holds great promise as a new therapeutic against clinically relevant secondary ALK mutations.Keywords
Funding Information
- National Key Research and Development Program of China (2017YFA0504504)
- National Key Research and Development Program of China (2016YFA0502001)
- Fundamental Research Funds for the Central Universities (20720190101)
- Xiamen Municipal Bureau of Science and Technology (3502Z20183006)
- Project 211 (B06016)
- National Natural Science Foundation of China (22025702)
- National Natural Science Foundation of China (91853203)
- National Natural Science Foundation of China (82021003)
- National Natural Science Foundation of China (82073874)
- National Natural Science Foundation of China (81890994)
This publication has 53 references indexed in Scilit:
- Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung CancerNew England Journal of Medicine, 2013
- Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivityNature Biotechnology, 2011
- PHENIX: a comprehensive Python-based system for macromolecular structure solutionActa Crystallographica Section D Structural Biology, 2010
- Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitorsNature, 2010
- electronic Ligand Builder and Optimization Workbench(eLBOW): a tool for ligand coordinate and restraint generationActa Crystallographica Section D Structural Biology, 2009
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityJournal of Computational Chemistry, 2009
- A mouse model for EML4-ALK -positive lung cancerProceedings of the National Academy of Sciences, 2008
- Phasercrystallographic softwareJournal of Applied Crystallography, 2007
- Coot: model-building tools for molecular graphicsActa Crystallographica Section D Structural Biology, 2004